The immunohistochemical expression of CD24 and CD171 adhesion molecules in borderline ovarian tumors

Abstract

CD24 and CD171 are cell adhesion proteins, which have been shown to be overexpressed in several carcinomas and to be associated with a poor clinical outcome. Our aim was to determine the expression of these two adhesion molecules in ovarian borderline neoplasms. We investigated 50 ovarian borderline tumors (serous, mucinous and endometrioid) as well as 29 benign cystadenomas and 25 carcinomas, which were used as controls. Paraffin sections were stained immunohistochemically for CD24 and CD171, and their expression was recorded in a semi-quantitative manner. In normal epithelium and benign ovarian cystadenomas both the CD24 and CD171 expression was negative to low, while their expression was significantly increased in borderline and malignant ovarian tumors. High-grade carcinomas, and carcinomas with metastases to the omentum presented considerably higher CD24 expression than low-grade carcinomas, and carcinomas without metastases. In addition, a few borderline and many malignant tumors presented cytoplasmic CD24 immunoreactivity, whereas all benign and most borderline tumors showed apical localization of this molecule. In conclusion, borderline tumors and carcinomas of the ovary present increased expression of CD24 and CD171 in relation to their benign counterparts, as is the case in malignant tumors of other organs. Change of staining pattern of CD24 (apical to cytoplasmic) apparently relates to a more aggressive phenotype.

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer

“…Its expression in ovarian cancer has previously been studied using immunohistochemistry [19–22] where the presence of L1CAM was associated with an adverse clinical outcome. Furthermore, the L1CAM expression was analyzed using a quantitative ELISA in ascitic fluid of serous ovarian carcinoma.…”

“…Outside of neuronal tissue L1CAM expression was found to be associated with various human malignant tumors [14] such as pancreatic tumors, colon cancer, melanoma, renal cell and endometrial carcinoma and was linked to a poor prognosis [15–18]. In ovarian cancer L1CAM expression was previously studied by immunohistochemistry (IHC) on paraffin-embedded samples [19–22] and by enzyme-linked-immunosorbant assay (ELISA) as well in lysates of serous ovarian cancers as in the corresponding ascitic fluid [23, 24]. However, in contrast to other tumor entities results remained conflicting in ovarian cancer.…”

Overview of CD24 as a new molecular marker in ovarian cancer

“…The first evidence for CD24 expression in OC was achieved on RNA level using microarray technology (Welsh et al, 2001). The immunohistochemistry (IHC) analysis completed these data and showed CD24 overexpression in OC specimens (Moulla, Miliaras, Sioga, Kaidoglou, & Economou, 2013). The CD24 expression and its significance in OC tumors have been demonstrated in several studies that will be discussed below:…”

Panels of protein biomarkers and non-protein markers in the diagnosis of the ovarian cancer

“…paneli biomarkerów, czyli testów oznaczających kilka substancji jednocześnie, w celu uzyskania jak najwyższej czułości oraz specyficzności [16]. Przykładem skutecznego wykorzystania takich złożonych badań są dwa testy: algorytm ROMA oraz test OVA1.…”